CASP3 and Cerebral ischemia: This could lead to a significant decrease in the Bax/Bcl-2 ratio, cleaved caspase-3/caspase-3, p53 phosphorylation, and cytochrome c release, making it a potential medication to prevent or treat cerebral ischemia–reperfusion injury [263].